Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study.
JAK inhibitors
Spain
abrocitinib
atopic dermatitis
treatment
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Nov 2024
Nov 2024
Historique:
revised:
05
06
2024
received:
19
05
2024
accepted:
06
06
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
19
10
2024
Statut:
ppublish
Résumé
Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited. This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD. We conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters. The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were naïve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma. This first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.
Sections du résumé
BACKGROUND
BACKGROUND
Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.
OBJECTIVES
OBJECTIVE
This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.
METHODS
METHODS
We conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters.
RESULTS
RESULTS
The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were naïve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma.
CONCLUSIONS
CONCLUSIONS
This first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.
Substances chimiques
abrocitinib
73SM5SF3OR
Sulfonamides
0
Pyrimidines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e289-e295Informations de copyright
© 2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.
Références
Silvestre Salvador JF, Romero‐Pérez D, Encabo‐Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88.
Sicras‐Mainar A, Navarro‐Artieda R, Armario‐Hita JC. Severe atopic dermatitis in Spain: a real‐life observational study. Ther Clin Risk Manag. 2019;15:1393–1401.
Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐Weller M, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744.
Simpson EL, Bruin‐Weller M, Flohr C, Ardern‐Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633.
Damiani G, Calzavara‐Pinton P, Stingeni L, Hansel K, Cusano F, “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale); Pigatto PDM. Italian guidelines for therapy of atopic dermatitis‐Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32(6):e13121.
Wollenberg A, Barbarot S, Bieber T, Christen‐Zaech S, Deleuran M, Fink‐Wagner A, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
Olydam JJ, Shlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37:2537–2542.
Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden‐Van Nes AMT, et al. Real‐world Experience of abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28‐week Results from the BioDay Registry. Acta Derm Venereol. 2024;104:adv19454.
Hu Y, Zhao Y, Li H, Zhou C, Yu C, Mu Z, et al. Good efficacy and safety profile of abrocitinib in Chinese adult patients with atopic dermatitis. A case series study. Chin Med J. 2024;137(6):740–742.
Uchiyama A, Kosaka K, Ishikawa M, Inoue Y, Motegi S. Real‐world effectiveness and safety of abrocinitib in 12 Japanese patients with atopic dermatitis and transcriptomic analysis with peripheral blood. J Dermatol. 2024;51(6):849–853.
Czarnowicki T, He H, Krueger JG, Guttman‐Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11.
Tong Z, Zbang Y, Zhoy K, Zou Y, Wu Z, Cben J, et al. An observational study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis after switching from dupilumab. J Am Acad Dermatol. 2023;89(4):826–828.
Bridgewood C, Wittmann M, Macleod T, Watad A, Newton D, Bhan K, et al. T Helper 2 IL‐4/IL‐13 dual blockade with dupilumab is linked to some emergent T helper 17–type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660–2667.
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate‐to‐severe atopic dermatitis: results from JADE MONO‐1, a randomized, phase 3 clinical trial. Lancet. 2020;396:255–266.
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis: a randomized phase 3 clinical trial. JAMA Dermatol. 2020;156:863–873.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86:104–112.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101–1112.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Ric ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, multicentre phase 3 trial. Lancet. 2022;400:273–282.